Lopid Articles
Statins lower cholesterol in HIV patients
16 March 2009
Editor's views on AstaZeneca Exanta woes and Bayer/S-P deal
20 September 2004
Bayer goes on the offensive over Baycol accusations
10 March 2003
Baycol-linked deaths reach 100, says Bayer
28 January 2002
Japan pharma stocks in week to August 27
29 August 2001
Bayer takes Baycol off Japanese market
24 August 2001
Japan pharma stocks: week to August 13
14 August 2001
France curbs PPA drugs, eyes cerivastatin
20 July 2001
Bayer pulls higher dose of Lipobay in UK
5 July 2001
Spanish drugmakers adapt to advent of generics regime
15 September 2000
Kos sees promise with Niaspan in raising HDL
18 May 2000
Gemfibrozil cuts risk in low HDL cardiac cases
4 August 1999
Greece To Slim Official Drug List
4 February 1998
Warner-Lambert Sells Generics Business
11 March 1996
cholesterol-lowering agents implicated as carcinogens
15 January 1996
Improved Third Quarter For Teva Pharmaceutical
20 November 1995
Disappointing Second Quarter From Teva
14 August 1995
Atorvastatin Superior To Other Statins?
24 April 1995
Generic Gemfibrozil Approval For Mylan
13 March 1995
Analysts' Eyes On Warner-Lambert
20 February 1995
End Of Year Encouraging For US Companies
6 February 1995
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
WEST POINT EXPANDS PRODUCT LINE
9 May 1994
JAPAN PHARMA MARKET IS LARGE, POOR PERFORMER
14 March 1994
CURRENCY AND CHARGES IMPACT 1993 US RESULTS
7 February 1994
WARNER LAMBERT GIVES UP PATENT
17 January 1994
103% NET INCOME RISE FOR ISRAEL's TEVA
22 November 1993
HOECHST CELANESE ACQUIRES US GENERICS CO
25 October 1993
NORTH AMERICAN NEWS IN BRIEF
4 October 1993
WARNER-LAMBERT CONSENT AGREEMENT
23 August 1993
ALL HOPES ON COGNEX AT WARNER-LAMBERT
26 April 1993
TACRINE CLEARS APPROVAL HURDLE
29 March 1993
US 4th QTR SHOWS NOT ALL COMPANIES STRONG
15 February 1993
JOUVEINAL PRODUCTS EFFECT ON W-L PIPELINE
8 February 1993
RECORD RESULTS FROM US PHARMA MAJORS
1 February 1993
Lipidwatch launch
6 July 1992
WARNER-LAMBERT EARNINGS FORECAST
29 June 1992
STOCK MARKET COMMENTARY: NEW YORK
25 May 1992
NEW DELIVERY SYSTEM FROM ALZA
18 May 1992
MYLAN TO MARKET GEMFIBROZIL IN USA
27 April 1992
WARNER-LAMBERT'S VIEW TO THE FUTURE
27 April 1992
GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR
27 April 1992
OPTIMISTIC ANALYSIS OF WARNER-LAMBERT
13 April 1992
HYPOLIPIDEMICS INFO
23 March 1992
STOCK MARKET COMMENTARY: NEW YORK
9 March 1992
VOLUME GROWTH FOR US DRUGMAKERS
9 March 1992
BOOTS TO COPROMOTE W-L'S LOPID
10 February 1992
Showing 1-53 of 53 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
